The technology behind the modern sMPC algorithms has not always been perfect, however, many steps have been taken to push the technology further. A good example of this progress is the development ...

Herceptin has relatively few side effects, but certainly the one that has troubled us the most is that there is a small, but real, chance of developing heart damage as a consequence of Herceptin, ...

Herceptin’s US sales were just over $2.9 billion last year, and globally they were nearly $6.8 billion, and it has been off-patent in Europe since 2014.

An aggressive type of breast cancer — a HER2-positive tumor — often shrinks with Herceptin treatment, but side effects can be tough. Researchers say a shorter course of the drug may be a good ...

The breast cancer drug Herceptin prevents breast cancer from coming back in some women, new research shows. Moreover, Herceptin works just as well with and without Adriamycin, a chemotherapy drug ...

Providing Herceptin to a select group of breast cancer patients would effectively double the cost of treatment and add $150-million a year to the health-care tab.

Wider Use Of Herceptin Approved November 17, 2006 / 2:00 PM EST / WebMD The FDA will allow Herceptin, a biological cancer drug, to be used to treat an aggressive type of breast cancer after surgery.

Worldcoin Foundation’s SMPC system SMPC has been lauded by privacy and security experts alike. It can be thought of as taking one secret and sharing it in multiple parts across different parties ...

HER2 is short for human epidermal growth factor receptor 2. Researchers discovered HER2 breast cancer in the 1980s. Too many copies of the HER2 gene or its overexpression appeared to cause an ...

The breast cancer drug Herceptin has been approved for use on the NHS for the treatment of early stage breast cancer. The decision by the National Institute for Clinical and Health Excellence (NICE) ...

British Journal of Cancer - Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. ... F. Hoffmann-La Roche Herceptin SmPC (2011) ...